Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
The authors applied a rigorous statistical approach, mediation analysis, to examine the mediating effect of smoking behavior and self-reported, physician-diagnosed emphysema (chronic obstructive pulmonary disease [COPD]) on the relation between the CHRNA5-A3 region genetic variant rs1051730 and the risk of lung cancer.
|
20564069 |
2010 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
Two SNPs (rs6495309 and rs1051730) located in nicotinic acetylcholine receptor alpha 3 (CHRNA3) gene were genotyped in 1511 patients with COPD, 1559 lung cancer cases and 1677 controls in southern and eastern Chinese populations.
|
23056235 |
2012 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
In the LEUVEN cohort, rs1051730 AA-carriers and rs8034191 GG-carriers had a two-fold increased risk to suffer from COPD GOLD IV (OR 2.29, 95% confidence interval [CI] = 1.11-4.75; p = 0.025 and OR = 2.42, 95% [CI] = 1.18-4.95; p = 0.016, respectively).
|
23349703 |
2013 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
In this study, we compared genetic variants influencing the effect of smoking on COPD, that is, the effect of the well-known splicing defect polymorphism, CYP3A5*3 (rs776746), identified before genome-wide association studies, with the genome-wide association studies identified CHRNA3 (rs1051730) polymorphism on the risk of decreased lung function and COPD.
|
24535486 |
2014 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
Our study showed the association of rs13180, rs16969968 and rs1051730 with COPD and lung function in Tatar population from Russia.
|
28474623 |
2016 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
Our analysis revealed that effects of two linked variants (rs1051730 and rs8034191) in the AGPHD1/CHRNA3 cluster on COPD development are significantly, yet not entirely, mediated by the smoking-related phenotypes.
|
23299987 |
2013 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
Cox-proportional hazards models were used to determine the correlation between rs1051730 and incidence of first COPD, tobacco-related cancer, other cancer and cardiovascular disease (CVD), and total mortality due to these causes, during approximately 14 years of follow-up.
|
26689306 |
2016 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
In ever-smokers, the CHRNA3 rs1051730 genotype associated with reduced lung function and increased COPD severity.
|
22441734 |
2012 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
Four SNPs (rs1964678, rs12593229, rs965604 and rs13180) in IREB2 were associated with forced expiratory volume in 1 s (FEV(1))% predicted and three SNPs (rs16969968, rs8034191 and rs1051730) in CHRNA3/5 were both associated with FEV(1)% predicted and FEV(1)/FVC in COPD cases (P range 0.007-0.050).
|
22914670 |
2012 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
GWASDB |
Identification of FGF7 as a novel susceptibility locus for chronic obstructive pulmonary disease.
|
21921092 |
2011 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
Our findings suggest that rs1051730 in CHRNA is a susceptibility variant for COPD, in terms of both airway obstruction and parenchyma destruction.
|
22176972 |
2011 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
Although rs1051730 and rs6495309 were shown to be independent risk factors for COPD, validation studies should be performed.
|
25051068 |
2014 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
In addition, the A alleles in CHRNA3 rs1051730 and CHRNA5 rs16969968 were associated with the risk for LC (OR = 1.66, P = 0.07 and OR = 1.57, P = 0.1, respectively) and for COPD (OR = 2.04, P = 0.01 and OR = 1.91, P = 0.02, respectively).
|
29993116 |
2018 |
Chronic Obstructive Airway Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
The FPRP test results were as follows: 1) when the prior probability was 0.001 and the OR was 1.5, ADAM33 rs612709, CHRNA3/5 rs1051730, CHRNA3/5 rs8034191, CHRNA3/5 rs16969968, and TGFB1 rs1800470 were truly associated with COPD risk (FPRP < 0.2); 2) when the prior probability was 0.000001 and the OR was 1.5, all the variants except TGFB1 rs1800470 remained noteworthy; and 3) when the probability was 0.000001 and the OR was 1.2, ADAM33 rs612709 and CHRNA3/5 rs1051730 remained true positives.
|
27323020 |
2016 |
Adenocarcinoma of lung (disorder)
|
|
0.810 |
GeneticVariation
|
BEFREE |
The top two CHRNA3 SNPs associated with the risk for lung adenocarcinoma were rs1051730 and rs12914385 (p-value = 1.9×10(-10) and 1.1×10(-10), respectively).
|
25233467 |
2014 |
Malignant neoplasm of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The increase in cotinine levels indicated an increased risk of lung cancer with each additional copy of the rs1051730-rs16969968 risk allele (per-allele odds ratio = 1.31, 95% CI = 1.21 to 1.42).
|
22534784 |
2012 |
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
In conclusion, this meta-analysis demonstrated that the two common variations (rs8034191 and rs1051730) at 15q25 are a risk factor associated with increased LC susceptibility, but these associations vary in different ethnic populations.
|
24254305 |
2014 |
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The nicotinic acetylcholine receptor polymorphism (rs1051730) on chromosome 15q25 is associated with major tobacco-related diseases in the general population with additional increased risk of COPD as well as lung cancer.
|
23061658 |
2012 |
Malignant neoplasm of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Associations of SNPs in LOC123688 (rs10519203; odds ratio [OR] = 1.60, 95% confidence interval [CI] = 1.25 to 2.05, P = .00016), CHRNA5 (rs2036527; OR = 1.67, 95% CI = 1.26 to 2.21, P = .00031), and CHRNA3 (rs1051730; OR = 1.81, 95% CI = 1.26 to 2.59, P = .00137) genes with lung cancer risk reached Bonferroni-corrected levels of statistical significance (all statistical tests were two-sided).
|
20554942 |
2010 |
Malignant neoplasm of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Smoking behavior and COPD are mediators of the association between the single nucleotide polymorphism (SNP) rs1051730 and the risk of lung cancer.
|
20564069 |
2010 |
Malignant neoplasm of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
We observed a significant association between lung cancer and rs1051730 in pooled population by using allele (OR = 1.30, 95% CI = 1.27-1.34, P < 0.0001), dominant (OR = 1.41, 95% CI = 1.29-1.55, P < 0.0001), recessive (OR = 1.53, 95% CI = 1.42-1.65, P < 0.0001) and additive (OR = 1.75, 95% CI = 1.61-1.90, P < 0.0001) models.
|
26508385 |
2015 |
Malignant neoplasm of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The nicotinic acetylcholine receptor polymorphism (rs1051730) on chromosome 15q25 is associated with major tobacco-related diseases in the general population with additional increased risk of COPD as well as lung cancer.
|
23061658 |
2012 |
Malignant neoplasm of lung
|
|
0.800 |
GeneticVariation
|
GWASDB |
Common 5p15.33 and 6p21.33 variants influence lung cancer risk.
|
18978787 |
2008 |
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
We observed a significant association between lung cancer and rs1051730 in pooled population by using allele (OR = 1.30, 95% CI = 1.27-1.34, P < 0.0001), dominant (OR = 1.41, 95% CI = 1.29-1.55, P < 0.0001), recessive (OR = 1.53, 95% CI = 1.42-1.65, P < 0.0001) and additive (OR = 1.75, 95% CI = 1.61-1.90, P < 0.0001) models.
|
26508385 |
2015 |
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, the authors apply a novel method for mediation analysis, allowing for gene-environment interaction, to a lung cancer case-control study (1992-2004) conducted at Massachusetts General Hospital using 2 single nucleotide polymorphisms, rs8034191 and rs1051730, on 15q25.1.
|
22306564 |
2012 |